Kathy Bergsteinsson
Chief Financial Officer @ Affini-T Therapeutics
About Kathy Bergsteinsson
Kathy Bergsteinsson is the Chief Financial Officer with a strong background in finance, having previously led over 70 IPOs and managed more than $100 billion in equity financing at Morgan Stanley.
Known information
Kathy Bergsteinsson serves as the Chief Financial Officer, bringing a robust expertise in financial management and strategic transactions. She began her career in the mergers and acquisitions department at Morgan Stanley, where she advised on transactions totaling over $100 billion. Kathy later transitioned to become the Managing Director and Head of Healthcare Equity Capital Markets at the same institution. In this role, she was instrumental in raising over $100 billion in equity financing for clients through more than 70 initial public offerings and 175 follow-on common stock offerings, convertible debt offerings, and private placement transactions. Kathy holds a Bachelor of Science degree in industrial engineering from Stanford University and a Master of Business Administration from The Wharton School at the University of Pennsylvania.
About Affini-T Therapeutics
Affini-T Therapeutics, based in Watertown, MA, develops TCR-based immunotherapies for solid tumors, focusing on oncogenic mutations such as KRAS and p53.